(Q35562614)

8 August 2017

title

Gefitinib therapy for advanced non-small-cell lung cancer (English)

1 reference

8 August 2017

Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer (English)

1 reference

22 March 2024

author name string

Susan Seen

series ordinal

2

1 reference

8 August 2017

Chin Y. Liu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14565788

22 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://journals.sagepub.com/doi/pdf/10.1345/aph.1D145

1 reference

http://journals.sagepub.com/doi/full-xml/10.1345/aph.1D145

22 March 2024

1 reference

Annals of Pharmacotherapy

22 March 2024

published in

1 reference

8 August 2017

volume

37

1 reference

8 August 2017

issue

11

1 reference

8 August 2017

page(s)

1644-1653

1 reference

8 August 2017

cites work

Cancer statistics, 2002

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

The epidermal growth factor receptor: a new target for anticancer therapy

21 January 2018

1 reference

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

21 January 2018

1 reference

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

21 January 2018

1 reference

ZD1839 (IRESSA): a selective EGFR-TK inhibitor

21 January 2018

1 reference

Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes

21 January 2018

1 reference

Tyrosine kinase inhibitors-ZD1839 (Iressa).

21 January 2018

1 reference

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

Epidermal growth factor receptor dependence in human tumors: more than just expression?

21 January 2018

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

21 January 2018

1 reference

ZD1839 (Iressa) in non-small cell lung cancer

21 January 2018

1 reference

Targeting epidermal growth factor receptor in lung cancer

21 January 2018

1 reference

ZD1839 ('Iressa') as an anticancer agent

21 January 2018

1 reference

21 January 2018

31

13

2

Giaccone G

2002

1 reference

22 March 2024

32

13

127

Johnson DH

2002

1 reference

22 March 2024

Identifiers

DOI

10.1345/APH.1D145

1 reference

8 August 2017

1 reference